Financial Instruments and Fair Value Measurements (Tables)

9 Months Ended

Jun. 26, 2015

Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis

The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:



	June 26, 2015		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	35.9	$	24.5	$	11.4	$	—
Foreign exchange forward and option contracts	3.6		3.6		—		—
	$	39.5	$	28.1	$	11.4	$	—

Liabilities:
Deferred compensation liabilities	$	20.1	$	—	$	20.1	$	—
Contingent consideration and acquired contingent liabilities	175.4		—		—		175.4
Foreign exchange forward and option contracts	0.9		0.9		—		—
	$	196.4	$	0.9	$	20.1	$	175.4



	September 26, 2014		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	35.7	$	22.9	$	12.8	$	—
	$	35.7	$	22.9	$	12.8	$	—

Liabilities:
Deferred compensation liabilities	$	15.0	$	—	$	15.0	$	—
Contingent consideration and acquired contingent liabilities	202.8		—		—		202.8
Foreign exchange forward and option contracts	0.2		0.2		—		—
	$	218.0	$	0.2	$	15.0	$	202.8

Schedule of Reconciliation of Changes in Fair Value of Contingent Liabilities



Balance at September 26, 2014	$	202.8
Payments	(29.0		)
Accretion expense	5.9
Effect of currency rate change	(4.3		)
Balance at June 26, 2015	$	175.4

Schedule of Carrying Amount and Fair Value of Long-term Debt

The following table presents the carrying values and estimated fair values of the Company's long-term debt, excluding capital leases, as of the end of each period:



	June 26, 2015				September 26, 2014
	Carrying Value		Fair Value		Carrying Value		Fair Value
Variable-rate receivable securitization	$	153.0	$	153.0	$	150.0	$	150.0
2.85% term loan due April 2016	—		—		3.1		3.1
3.50% notes due April 2018	300.0		301.5		300.0		290.2
4.875% notes due April 2020	700.0		715.0		—		—
Term loans due March 2021	1,977.8		1,977.2		1,990.3		1,970.4
4.00% term loan due February 2022	8.8		8.8		10.8		10.8
9.50% debentures due May 2022	10.4		13.1		10.4		14.2
5.75% notes due August 2022	900.0		927.8		900.0		907.3
8.00% debentures due March 2023	4.4		5.3		8.0		10.2
4.75% notes due April 2023	598.4		563.5		598.3		563.8
5.50% notes due April 2025	700.0		683.7		—		—

Schedules of Concentration of Risk

The following table shows net sales attributable to distributors that accounted for 10% or more of the Company's total net sales:



	Three Months Ended				Nine Months Ended
	June 26, 2015		June 27, 2014		June 26, 2015		June 27, 2014
CuraScript, Inc.	28	%	—	%	28	%	—	%
McKesson Corporation	9	%	24	%	14	%	18	%
Cardinal Health, Inc.	12	%	22	%	13	%	19	%
Amerisource Bergen Corporation	10	%	11	%	8	%	11	%

The following table shows accounts receivable attributable to distributors that accounted for 10% or more of the Company's gross accounts receivable at the end of each period:



	June 26, 2015		September 26, 2014
McKesson Corporation	27	%	24	%
Cardinal Health, Inc.	15	%	17	%
CuraScript, Inc.	15	%	13	%
Amerisource Bergen Corporation	10	%	13	%

The following table shows net sales attributable to products that accounted for 10% or more of the Company's total net sales:



	Three Months Ended				Nine Months Ended
	June 26, 2015		June 27, 2014		June 26, 2015		June 27, 2014
Acthar (Specialty Brands)	28	%	—	%	28	%	—	%
Optiray™ (CMDS)	6	%	12	%	6	%	13	%